Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (600671.SS)
Hangzhou, CN
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, a company founded in 1958 and based in Hangzhou, China, operates a multifaceted business primarily focused on the pharmaceutical sector. Through its various subsidiaries, the company specializes in both the production and distribution of medicines throughout China. Its extensive product range includes the manufacturing and sale of a diverse array of pharmaceuticals and health-related goods. These encompass various dosage forms such as tablets, granules, pills, mixtures, oral liquids, syrups, eye drops, and soft capsules, as well as a selection of health foods. Beyond finished products, Hangzhou TianMuShan is also involved in the trade of raw materials like menthol and peppermint oil. The company also offers a comprehensive selection of traditional Chinese medicine, including prepared formulas, individual herbal pieces, and fresh herbs. Furthermore, it provides specialized medical services such as custom decoction preparation and delivery, herbal slicing and powder grinding, and traditional Chinese medicine diagnosis and treatment. In addition to its core pharmaceutical activities, the enterprise has diversified into other ventures, including software development, remote health management solutions, commercial property administration, food services, and internet information businesses.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.29% | -7.77% | -12.31% | -18.11% | +0.81% | +0.87% | +35.56% | +138.52% | +105.90% | -48.08% | +179.04% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%-3.1% Q1'26: -15.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+7.7% Q1'26: -25.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%-16.4% Q1'26: -51.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+6.6% Q1'26: +16.9% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+4.2% Q1'26: +7.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×3.36× Q1'26: 6.22× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guojun Dang | Vice Chairman & Board Secretary | — | male |
| Hongjian Yu | Deputy GM, Chief Financial Officer, Accounting Supervisor & Director | — | male |
| Shengbin Ji | Deputy General Manager | — | male |
| Xuejian Sun | General Manager | — | male |
| Yinjun Li | Deputy General Manager | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600671.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
